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Abstract
In Australian prisons approximately 20% of inmates are chronically infected with hepatitis
C virus (HCV), providing an important population for targeted treatment and prevention. A
dynamic mathematical model of HCV transmission was used to assess the impact of
increasing direct-acting antiviral (DAA) treatment uptake on HCV incidence and preva-
lence in the prisons in New South Wales, Australia, and to assess the cost-effectiveness
of alternate treatment strategies. We developed four separate models reflecting different
average prison lengths of stay (LOS) of 2, 6, 24, and 36 months. Each model considered
four DAA treatment coverage scenarios of 10% (status-quo), 25%, 50%, and 90% over
2016–2045. For each model and scenario, we estimated the lifetime burden of disease,
costs and changes in quality-adjusted life years (QALYs) in prison and in the community
during 2016–2075. Costs and QALYs were discounted 3.5% annually and adjusted to
2015 Australian dollars. Compared to treating 10% of infected prisoners, increasing DAA
coverage to 25%, 50%, and 90% reduced HCV incidence in prisons by 9–33% (2-months
LOS), 26–65% (6-months LOS), 37–70% (24-months LOS), and 35–65% (36-months
LOS). DAA treatment was highly cost-effective among all LOS models at conservative
willingness-to-pay thresholds. DAA therapy became increasingly cost-effective with
increasing coverage. Compared to 10% treatment coverage, the incremental cost per
QALY ranged from $497-$569 (2-months LOS), -$280–$323 (6-months LOS), -$432–
$426 (24-months LOS), and -$245–$477 (36-months LOS). Treating more than 25% of
HCV-infected prisoners with DAA therapy is highly cost-effective. This study shows that
treating HCV-infected prisoners is highly cost-effective and should be a government prior-
ity for the global HCV elimination effort.
PLOS ONE







Citation: Kwon JA, Chambers GM, Luciani F,
Zhang L, Kinathil S, Kim D, et al. (2021) Hepatitis C
treatment strategies in prisons: A cost-
effectiveness analysis. PLoS ONE 16(2): e0245896.
https://doi.org/10.1371/journal.pone.0245896
Editor: Yury E. Khudyakov, Centers for Disease
Control and Prevention, UNITED STATES
Received: October 1, 2020
Accepted: January 8, 2021
Published: February 11, 2021
Copyright: © 2021 Kwon et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: AL is funded by a Practitioner Fellowship
from the National Health and Medical Research
Council of Australia (NHMRC, No.1137587). FL is
supported by NHMRC CDA fellowship, but the
funder did not have any additional role in the study
design, data collection and analysis, decision to
publish, or preparation of the manuscript. WB
received salary support from RTI Health Solutions,
but the funder did not have any additional role in
Introduction
Nearly 200,000 Australians have hepatitis C infection, a leading cause of liver-related deaths,
with around 400 deaths per 100,000 population are attributed to hepatitis C virus (HCV) infec-
tion in 2015 [1, 2]. Approximately two-thirds of new infections fail to resolve and persist for
life, resulting in an estimated 6,000 new cases of chronic HCV infection each year [2]. HCV is
the leading indication for liver transplantation and liver-related deaths in Australia and with-
out treatment, approximately 20–30% of those with chronic HCV will progress to cirrhosis,
liver failure or hepatocellular carcinoma [3]. The risk of acquiring infectious disease in the
prison setting is higher than in the general population including high rates of exposure to
blood-borne viral infections such as HCV.
Recent advances in HCV treatment have revolutionised the clinical management of viral
hepatitis. The development of direct-acting antiviral (DAA) therapy for HCV provides a safe
and highly effective cure rate of over 95% [4–8]. In March 2016, the Australian government
provided highly subsidized access to DAA therapy for people living with HCV, without restric-
tions on liver disease stage, drug and alcohol use, or prescriber type, with specific inclusion of
access for prisoners [9].
Prisoner populations are characterised by high rates of exposure to blood-borne viral infec-
tions such as HCV [10–15]. The prevalence of HCV antibodies in Australian prisons is high,
with one in five inmates chronically infected [16]. The most recent prevalence estimates sug-
gest that between 7,500 and 10,000 prisoners in Australia, are HCV antibody positive and
approximately 7,500 chronically infected with HCV [17]. A recent meta-analysis of HCV inci-
dence studies among prisoners revealed a mean incidence of 11.4 cases per 100 person-years
in the New South Wales, Australia [15]. The prisoner population in Australia, as in other coun-
tries, comprised mostly men with less than one in 10 prisoners in Australia identifying as
female [18]. Some gender differences in the prevalence of HCV are apparent [19].
Transmission of HCV in prison is strongly associated with injecting drug use and sharing
contaminated injecting equipment [14]. Around 8 in 10 people who inject drugs (PWIDs)
spend time in prison at some time in their lives with many cycling through on multiple occa-
sions [20]. Prisons can be regarded as an enclosed network of facilities within which prisoners
are frequently moved between sites due to changes in security classifications, to attend court
approaches, for safety reasons, or to obtain medical treatment. Among PWID in New South
Wales (NSW) prisons, Australia, the length of stay (LOS) before being released, is typically
short (average 7–9 months). Although prison-based hepatitis services have been established in
NSW for many years, the short incarceration period rendered treatment of prisoners with
interferon-based therapies difficult due to the 6 to 12-month treatment period, in addition to
the challenge for both the patients and service providers in managing the substantial side-
effects of these older treatments [21, 22]. However, the introduction DAA therapies, which
typically only require an 8 to 12-week course of once-daily, oral, very low side-effect and highly
curative treatment with a 95% cure rate [4–6] has provided an opportunity to cure those with
HCV infection whilst in prison, and so reduce the overall population burden of HCV infection
in the community. As such, prisons provide a potentially important setting to reduce the over-
all burden of HCV infection both in terms of treatment and prevention [23].
We developed a mathematical model that describes HCV transmission dynamics in the
NSW prison setting, accounting for key risk behaviours (e.g. injecting drug use), prison
dynamics (e.g. duration of incarceration), natural history of HCV-related liver disease, and
healthcare costs associated with DAA treatment interventions and burden of living with HCV.
Mathematical models are useful tools for understanding complex dynamical systems, such as
infectious disease epidemics and are typically used to study the mechanisms of disease spread
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and to predict future disease outbreaks. Future transmission of infectious disease epidemics
such as HCV are difficult to predict, but by using mathematical models to identify dominant
factors of disease transmission, future patterns of disease spread and impact can be predicted.
Mathematical models provide transparency, and the calibration phase of modeling enables
epidemiological assumptions to be tested by comparing model results with observed patterns
[24, 25]. By conducting a cost-effectiveness analysis using the output of mathematical models,
in this case implementation of DAA treatment regimes in the prison setting, the costs and
effects of interventions on targeting populations and of changing the level of intervention cov-
erage can also be evaluated.
Materials and methods
The mathematical model is compartmentalized and implemented as a system of ordinary dif-
ferential equations detailing sub-populations of prison inmates according to injecting drug
use, sharing of injecting apparatus, and liver disease status. The DAA treatment interventions
were modelled for 30 years in prison (2016–2045), with healthcare costs and quality-adjusted
life years (QALYs) tracked for a further 30 years post prison (2046–2075) to capture long-term
costs and health gains from high cure rates. We assumed status quo for 2016 with HCV treat-
ment coverage providing DAA treatment to 10% the prison population regardless of liver dis-
ease stage (F0 to F4) and genotype, using a nurse-led model of care [26]. The model
parameters are described in S1 and S2 Tables in S1 File.
The model tracks the acute stage (A) of HCV infection which results in spontaneous clear-
ance in 25% [27] of cases, each fibrosis stage (F0, F1, F2, F3 and F4 (compensated cirrhosis)),
decompensated cirrhosis and hepatocellular carcinoma, and the number of people who
received liver transplantation due to chronic HCV (See schematic diagram, Fig 1). The popula-
tion of people who leave prison after incarceration is tracked up to 2075 to account for the life-
time costs and changes in health-related quality of life of those treated and not treated. All
simulations and analyses were performed in MATLAB 2016a (The Mathworks, Natick, Massa-
chusetts, USA) and Microsoft Excel (Redmond, WA).
Model calibration
The model calibration was conducted using available data on HCV incidence and prevalence
(S1 Table in S1 File). The calibration was based on an observed decline in HCV antibody prev-
alence between 2001 and 2009 for the total prisoner population, but with a sustained HCV-Ab
prevalence of 70%+ among PWID [19].
Treatment and length of stay scenarios
Prisoners in NSW move frequently between prison locations, and between the community
and prisons. The analysis was performed on 4 settings with an average LOS of 2, 6, 24, 36
months respectively. The treatment scenarios were then applied for each LOS model from
2016 to 2045, with 10% (status-quo), 25%, 50%, and 90% treatment coverage [21].
Costs of treatment and care
The costs of treatment including the cost of the DAA medication and delivery under a nurse-
led model of care were assigned according to the perspective of the NSW Justice Health and
Forensic Mental Health Network and Corrective Services NSW, the former providing medical
services to prisoners in NSW and the latter security. Salaries for nursing and medical staff to
administer the treatment program and pharmacists’ were sourced from Australian
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Government’spublished pay scales [28]. The cost of the DAAs has been estimated at $15,000
Australian dollars (AUD) per patient for a 12-week course (consultation with an expert) [29],
and the cost of administration under the nurse-led model of care as $666 AUD based in bot-
tom up costing methods incorporating staff time and consumables.
Accordingly post-treatment, the annual public healthcare resources consumed for lifetime
care (burden of disease) associated with HCV infection and sequalae were calculated from a
healthcare perspective. Micro-costing methods were used to determine the unit costs and vol-
umes of the annual care of patients with HCV stages F0-F3 (first year and subsequent years),
F4 (compensated cirrhosis), decompensated cirrhosis, liver failure, and hepatocellular carci-
noma. Costs included specialist visits, clinical care nurse visits, pathology, medical procedures,
and hospital admissions. Unit costs were obtained from the Australian Medical Benefits
Scheme(assuming 100% government benefits) for medical services, procedures, and pathology
tests. Medication costs were sourced from the Australian Pharmaceutical Benefits Scheme [30,
31]. Inpatient medical procedures and hospital stays were sourced from the National Hospital
Cost Data Collection using Australian Refined Diagnosis Related Groups (AR-DRG 5.1) [32].
Costs were adjusted to 2015 AUD and discounted at 3.5% annually to reflect the future long-
term value of the costs incurred in treating and living with HCV infection [33].
Cost-effectiveness analysis
The cost-effectiveness analysis applied the costs and QALYs to the forecasted epidemiological
outcomes using the trajectory of HCV infection among Australian prison detainees over a
treatment period of 2016–2045, and follow-up period to 2075. Health state utilities used in the
Fig 1. Schematic diagram of HCV disease progression among prisoners in Australia. Each arrow represents the rate of
change in the number of people in the population moving from one health state compartment to another health state
compartment.
https://doi.org/10.1371/journal.pone.0245896.g001
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derivation of the QALYS were obtained from the literature and attached to each liver disease
stage [34]. QALYs were also discounted by 3.5% per annum. The costs and utility weights used
in the analysis can be found in S2 Table in S1 File. The key epidemiological indicators for the
cost-effectiveness analysis included the number of new HCV cases, HCV-related deaths and
number of people on treatment.
Incremental cost-effectiveness ratios (ICERs) were reported separately for the four LOS
models (2, 6, 24, 36 months). Within each model a pair-wise comparison was conducted
between 10% DAA coverage with 25%, 50% and 90% coverage of HCV-infected inmates,
resulting in 12 scenarios. The ICER was expressed as the incremental change in total costs and
QALYs relative to 10% DAA coverage for each LOS scenario. Strategies were considered to be
cost-effective if they generated an ICER less than the willingness-to-pay threshold (lambda)
considered to represent good value for money for healthcare interventions in Australia
($28,000 per QALY gained) [35].
The uncertainty around the costs and QALYs was explored through probabilistic sensitivity
analysis (PSA) [36]. This was undertaken using 5,000 Monte Carlo simulations which repeat-
edly creates random data through bootstrapping. A Gamma probability distribution was
assigned to the cost parameter computed from the variation of costs in treatment coverage
(10%, 25%, 50%, 90%) [37]. The QALYs were assigned a normal distribution with standard
deviations calculated from QALYs resulting from each treatment coverage. The PSA allowed
the estimation of 95% CI for the ICERs from the bootstrapped replications of data using the
percentile approach with a lower and upper percentile of 0.025 and 0.975, respectively [37].
Bootstrapping was performed in Microsoft Excel version 16 and implemented using a Micro-
soft Excel macro.
A Net Monetary Benefit (NMB) approach was also used allowing multiple alternatives to be
assessed for cost-effectiveness without requiring repeated pair-wise comparisons and allows the
most cost-effective alternative to be easily identified for different willingness-to-pay thresholds.
The NMB is defined as: (lambda x (incremental effect)–(incremental cost)). NMB is calculated
by assuming a threshold for willingness-to-pay, then converting QALYs into the corresponding
dollar values. The cost associated with each treatment strategy is then subtracted by the baseline
scenarios, resulting in the net benefit of each strategy expressed in the monetary units.
Results
The model predicted a sharp decline in new HCV infections in all LOS scenarios (Fig 2). Simu-
lations with an increased treatment coverage reduced HCV incidence rate by 9–33%
(2-months LOS), 26–65% (6-months LOS), 37–70% (24-months LOS), and 35–65%
(36-months LOS), showing that HCV treatment coverage was the major factor in reducing
HCV infections particularly in the longer LOS models of 6 or greater months.
Analysis of prevalence showed a linear increase over time, regardless of the average LOS,
and lower prevalence with higher treatment coverage (Fig 2). The incidence and prevalence of
chronic HCV remained relatively high and showed less impact of treatment coverage in the 2
months LOS model because of the high turn-over of HCV infected patients in these prisons.
Similarly, the prevalence of chronic HCV was lowest with 36 months LOS, because the lower
number of people coming into the population corresponds to a reduced incidence rate
(Table 1). Except for the 2 months LOS, from 50% DAA coverage, increasing LOS did not play
a major role in reducing the prevalence of HCV, but increases in treatment coverage reduced
the prevalence of HCV. Chronic HCV prevalence was 18,045, 21,573, 19,731, and 19,162 with
10% DAA coverage in 2 months, 6 months, 24 months, and 36 months LOS scenarios, respec-
tively. We estimated that an increase in DAA treatment coverage from 10% to 90% would
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avert 2,793 (15% reduction), 7,398 (34% reduction), 6,943 (35% reduction), and 6,133 (32%
reduction) HCV cases during 2015–2045 in the 2 months, 6 months, 24 months, and 36
months LOS, respectively (Table 1).
The number of NSW male prisoners treated between 2016–2045 ranged from 21,473 in the
36-month average LOS in prison with 10% coverage to 176,985 prisoners in the 2-month aver-
age LOS in prison with 90% coverage. The total cost attributed to the treatment of HCV-
infected prisoners over a 30-year treatment period (2016–2045) plus the lifetime cost of care
for a further 30 years ranged from $3,469 to $3,997 million with 10% DAA coverage (Table 2).
Increasing coverage to 90% of infected prisoners during the same period, would incur an addi-
tional $515-$1,061 million.
Treating 25% of infected prisoners was less costly and more effective for all LOS except 2
months LOS. The cost per QALY gained increased with increasing DAA coverage. For exam-
ple, for the 6-month average LOS prison model; compared to 10% treatment coverage of HCV
infected prisoners, treating 25%, 50%, and 90% of infected prisoners resulted in ICERs of
-$280, $88, and $323, respectively. Similarly, for the 36-month average LOS prison model,
treating 25%, 50%, and 90% of infected prisoners resulted in ICERs of -$245, $268, and $477,
respectively (Table 2 and Fig 3). Adopting a conservative maximum willingness-to-pay for
healthcare interventions threshold of $28,000 per QALY gained, indicates that across prison
settings and all LOS, DAA therapy is highly cost-effective, and cost saving as this level. The
results are confirmed by the positive NMB at all levels of coverage, with an economic surplus
of $6–10,000 per treated prisoner at 25% coverage, $19–20,000 per treated prisoner at 50%
coverage, and over $40,000 per treated prisoner at 90% coverage (Table 2).
Fig 2. Effect of length of stay (LOS) in prison (2 months LOS (a,b), 6 months LOS (c,d), 24 months LOS (e,f), 36
months LOS (g,h)) and treatment coverage (blue lines: 10% DAA, red lines: 25% DAA, orange lines: 50% DAA, purple
lines: 90% DAA) on the incidence (per 100 py) and prevalence of chronic HCV in prison.
https://doi.org/10.1371/journal.pone.0245896.g002
Table 1. Estimated HCV-related outcomes with treatment scenarios and length of stay (best estimate).
Incidence rate (2015, per 100 py) 11
People living with chronic HCV (2015) 9,623
10% DAA 25% DAA 50% DAA 90% DAA
Incidence rate (2045, per 100 py)
2 months length of stay 10.3 9.4 8.2 6.9
6 months length of stay 8.6 6.4 4.5 3.0
24 months length of stay 6.0 3.8 2.5 1.8
36 months length of stay 5.4 3.5 2.5 1.9
People living with chronic HCV (2045)
2 months length of stay 18,045 17,311 16,351 15,252
6 months length of stay 21,573 18,700 16,149 14,175
24 months length of stay 19,731 16,117 14,017 12,788
36 months length of stay 19,162 15,806 14,023 13,029
Cumulative liver-related deaths (2015–2045)
2 months length of stay 27,104 27,075 27,042 27,008
6 months length of stay 32,344 32,110 31,936 31,817
24 months length of stay 33,140 32,476 32,151 31,981
36 months length of stay 32,679 31,917 31,573 31,400
PY, person-years; HCV, hepatitis C virus; DAA, direct-acting antiviral.
https://doi.org/10.1371/journal.pone.0245896.t001
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Discussion
Using a dynamic model of HCV transmission, compared to treating 10% of HCV-infected
prisoners, the incidence of HCV infection in NSW prison was reduced by 26% to 70% depend-
ing on the average LOS in prison and the uptake of DAA therapy. Taking into account the cost
of treatment and lifetime care costs of living with HCV, our model indicates that DAA therapy
is increasingly cost-effective with increasing coverage in prisons among all LOS and at least
25% coverage of HCV-infected inmates. All ICERs for an HCV-infected prisoner were below
$500 when life-long health-related quality of life were considered which is lower than the
Table 2. Cost-effectiveness analysis of HCV treatment in prison, by length of stay and DAA treatment coverage, AUD 2015, mean (lower-upper).
Scenarios Cumulative number treated
(2016–2045)





WTP = $28,000 WTP = $100,000
2 months length of stay
10%
DAA
22,388 $3,680 $(3,637–3,723) 1.36 (1.35–1.38) - - -
25%
DAA






















6 months length of stay
10%
DAA
24,339 $3,997 $(3,950–4,044) 1.52 (1.51–1.53) - - -
25%
DAA




















24 months length of stay
10%
DAA
22,054 $3,559 $(3,518–3,599) 1.41 (1.40–1.42) - - -
25%
DAA






















36 months length of stay
10%
DAA
21,473 $3,469 $(3,432–3,506) 1.41 (1.40–1.43) - - -
25%
DAA






















Note: ICER = Incremental costs/incremental QALYs, NMB = Willingness to pay � incremental QALYs–incremental costs.
HCV, hepatitis C virus; DAA, direct-acting antiviral; QALYs, quality-adjusted life years; ICER, incremental cost-effectiveness ratio; NMB, Net Monetary Benefit; WTP,
willingness-to-pay; M, million.
https://doi.org/10.1371/journal.pone.0245896.t002
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Australia’s willingness-to-pay threshold $28,000 per QALY gained, and thus considered good
value for money in terms of healthcare expenditure.
Most of the benefit from treatment in prisons is realized in the community following
release. Our model therefore not only looked at the reduction in HCV prevalence in prison,
but also the long-term cost, health-related quality of life and cost-effectiveness of DAA therapy
when prisoners are released back to the community. The fact that much of the costs associated
with treatment is carried by the state prison budgets (in our study Corrective Services NSW
and Justice Health & Forensic Mental Health Network) rather than national healthcare budget
suggests that prison budgets should be compensated for the health and custodial infrastructure
costs of delivery of the DAA treatment, where drug costs are covered by the Commonwealth
Government of Australia.
Ensuring access to treatment for large numbers of individuals with chronic HCV infection
has put prisons firmly in the spotlight as a setting in which to identify and treat large numbers
of hard-to-reach individuals impacted by HCV [23]. International guidelines recommend pri-
oritization of the HCV treatment in PWID and prisoners, and that current injecting drug use
should not be a contraindication [38]. Even in the constrained public healthcare system in the
USA, the importance of HCV screening and treatment in prison can reduce the increasing
incidence of new infections and cases of advance liver diseases and liver-related deaths [39]
has been highlighted and considered “. . .a reasonable expenditure for correctional systems”,
and that doing so “. . .may be a worthy target for public health dollars” [40].
Fig 3. ICER plane for (a) 2 months, (b) 6 months, (c) 24 months, and (d) 36 months length of stay. Triangle shape represents 25% of people receive DAA,
diamond shape represents 50% DAA, and cross shape represents 90% DAA.
https://doi.org/10.1371/journal.pone.0245896.g003
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To our knowledge, only one other study has specifically investigated the cost-effectiveness
of DAA treatment in the prison setting [41]. This study used a Markov based model, and also
concluded that DAA treatment was cost-effective at $25,000-$30,000 per QALY gained. How-
ever, this study compared traditional interferon-based therapies with 3-drug regimens that
included the DAA (sofosbuvir) [41].
The strength of this study is that it investigates several treatment scenarios in prison and
included the long-term cost and outcomes both in prison and the community associated with
HCV treatment and care. A limitation of this study is that is does not track reinfection of those
treated, that is, it assumes that once cured individuals it goes back to the susceptible popula-
tion. The rates of reinfection in inmates are relatively high, estimated to be 5.27 cases per 100
person years under older interferon-based treatments [42]. However, given that acceptability
DAA treatment and shorted treatment time needed to reach sustained virologic response
(SVR), reinfections are likely to be lower than this [43]. The model did not consider future
pharmaceutical developments during the thirty years prison time. It is possible that less costly
treatments will become available during this time. Another limitation of our study is that we
did not model the effect of treatment as prevention, and indeed prevention is essential to opti-
mizing the benefits for HCV treatment to the population. A number of modeling studies have
indicated that even moderate levels of treatment can lead to a significant reduction in the prev-
alence and incidence of HCV infections [44–47]. Therefore, our cost-effectiveness estimates
are likely to be conservative, and thus even more cost-effective if the prevention of incident
HCV cases in the population were included. Our model did not include testing strategies
which can play an important role in detecting people who are living with HCV but are undiag-
nosed. A recent modeling study suggests that increased testing is important to eliminate HCV
transmission in Australia [48]. Future work should also include modeling of screening strate-
gies, linkage to HCV care, and the post-cure management to minimize reinfection of those
who are cured, and the impact of HCV treatment in female versus male prisons.
In conclusion, treating HCV-infective prisoner is highly cost-effective and should be a pri-
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